Home | Contact Us | Log In
(888) 789-6604
Report Stack
Advanced search
Account Detail 0 items in basket
Order History Total $
Saved Searches View Basket basket
Gedeon Richter Plc - Product Pipeline Review - 2012
Publication Date Aug 2012
Publisher Global Markets Direct
Product Type Report
Pages 71
Single User License help $ 1500.00
Site User License help $ 3000.00
Corporate User License help $ 4500.00
 

Reportstack.com does not charge credit card fee, transaction charges, extra tax or VAT on any purchase.

Gedeon Richter Plc - Product Pipeline Review - 2012

Summary

Global Markets Direct’s pharmaceuticals report, “Gedeon Richter Plc - Product Pipeline Review - 2012” provides data on the Gedeon Richter Plc’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Gedeon Richter Plc’s corporate website, SEC filings, investor presentations and featured press releases, both from Gedeon Richter Plc and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Gedeon Richter Plc - Brief Gedeon Richter Plc overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Gedeon Richter Plc human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Gedeon Richter Plc with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Gedeon Richter Plc’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Gedeon Richter Plc’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Gedeon Richter Plc in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Gedeon Richter Plc’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Gedeon Richter Plc.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Gedeon Richter Plc and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of Gedeon Richter Plc; Gedeon Richter Plc - Key Therapeutics; Gedeon Richter Plc - Pipeline Overview and Promising Molecules; Gedeon Richter Plc - News; Gedeon Richter Plc - Latest Updates; Gedeon Richter Plc - Pipeline; Gedeon Richter Plc - Discontinued/Dormant Projects

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Gedeon Richter Plc Snapshot 6
Gedeon Richter Plc Overview 6
Key Information 6
Key Facts 6
Gedeon Richter Plc - Research and Development Overview 7
Key Therapeutic Areas 7
Gedeon Richter Plc - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Gedeon Richter Plc - Pipeline Products Glance 11
Gedeon Richter Plc - Late Stage Pipeline 11
Phase III Products/Combination Treatment Modalities 11
Gedeon Richter Plc Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Gedeon Richter Plc - Drug Profiles 13
Cariprazine 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
Gedeon Richter Plc - Pipeline Products by Route of Administration 15
Gedeon Richter Plc - Pipeline Products By Mechanism of Action 16
Gedeon Richter Plc - Recent Pipeline Updates 17
Gedeon Richter Plc - Dormant Projects 19
Gedeon Richter Plc - Discontinued Pipeline Products 20
Discontinued Pipeline Product Profiles 20
Radiprodil 20
Gedeon Richter Plc - Company Statement 21
Gedeon Richter Plc - Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Gedeon Richter Plc, Recent Developments 27
Gedeon Richter Plc- Press Release 27
May 04, 2012: Forest To Present Cariprazine Results From Phase III Trial At American Psychiatric Association Annual Meeting 27
Feb 28, 2012: Forest Laboratories And Gedeon Richter Announce Results From Two Positive Phase III Trials With Cariprazine For Treatment Of Schizophrenia 27
Feb 08, 2012: Forest Laboratories And Gedeon Richter Announce Positive Phase III Results Of Cariprazine In Patients With Acute Mania Associated With Bipolar I Disorder 29
Oct 29, 2009: Forest Laboratories, Inc. And Gedeon Richter Announce Positive Results from A Phase IIb Study Of Cariprazine For The Treatment Of Schizophrenia. 30
Financial Deals Landscape 32
Gedeon Richter Plc, Deals Summary 32
Gedeon Richter Plc, Pharmaceuticals & Healthcare, Deal Details 34
Asset Transactions 34
Gedeon Richter Acquires Oral Contraceptive Portfolio From Grunenthal 34
Partnerships 36
Gedeon Richter Forms Joint Venture With Rxmidas Pharma 36
Gedeon Richter Enters Into Research Agreement With Astron Research 37
HRA Pharma Enters Into Co-Marketing Agreement With Gedeon Richter 38
Gedeon Richter Enters Into A Distribution Agreement With Orexo 39
ProStrakan Enters Into Distribution Agreement With Gedeon Richter 40
Gedeon Richter Enters Into An Agreement With Repros Therapeutics 41
KV Pharma Acquires Rights From Gedeon Richter 42
Licensing Agreements 43
DSM Biologics And Crucell Enter Into Licensing Agreement With Gedeon Richter 43
Gedeon Richter Enters Into Licensing Agreement With Mitsubishi Pharma 44
Gedeon Richter Expands Licensing Agreement With HRA Pharma 45
Phosphagenics Enters Into Licensing Agreement With Themis Medicare 46
Watson Labs Enters Into Licensing Agreement With PregLem For Esmya 47
Gedeon Richter Enters Into Licensing Agreement With Mochida Pharma 49
PregLem Enters Into Licensing Agreement With Merck Serono 50
PregLem Enters Into Licensing Agreement With HRA Pharma 52
KV Pharma Enters Into Licensing Agreement With Gedeon Richter 53
HRA Pharma Enters Into Licensing Agreement With PregLem 54
Ipsen Signs An Agreement With Preglem 55
Acquisition 56
Gedeon Richter Acquires PregLem From Ipsen And Sofinnova 56
Gedeon Richter Acquires 50% Stake In Medimpex UK From EGIS Pharma 59
Gedeon Richter Acquires 29.6% Stake In Grodziskie Zaklady Farmaceutyczne 60
Hungaropharma Acquires Medimpex Pharma From Gedeon And EGIS 62
Gedeon Richter Acquires 80.62% Stake Of Akrihin 64
Gedeon Richter Acquires 95.78% Stake In Pharmafarm 66
Gedeon Richter And Helm Acquire Strathmann Biotec 67
Armedica Trading Acquires Dita Group 69
Appendix 70
Methodology 70
Coverage 70
Secondary Research 70
Primary Research 70
Expert Panel Validation 70
Contact Us 71
Disclaimer 71

List of Tables
List of Tables
Gedeon Richter Plc, Key Information 6
Gedeon Richter Plc, Key Facts 6
Gedeon Richter Plc - Pipeline by Indication, 2012 8
Gedeon Richter Plc - Pipeline by Stage of Development, 2012 9
Gedeon Richter Plc - Monotherapy Products in Pipeline, 2012 10
Gedeon Richter Plc - Phase III, 2012 11
Gedeon Richter Plc - Phase II, 2012 12
Gedeon Richter Plc - Pipeline By Route of Administration, 2012 15
Gedeon Richter Plc - Pipeline Products By Mechanism of Action, 2012 16
Gedeon Richter Plc - Recent Pipeline Updates, 2012 17
Gedeon Richter Plc - Dormant Developmental Projects,2012 19
Gedeon Richter Plc - Discontinued Pipeline Products, 2012 20
Gedeon Richter Plc, Other Locations 24
Gedeon Richter Plc, Subsidiaries 25
Gedeon Richter Plc, Deals Summary 32
Gedeon Richter Acquires Oral Contraceptive Portfolio From Grunenthal 34
Gedeon Richter Forms Joint Venture With Rxmidas Pharma 36
Gedeon Richter Enters Into Research Agreement With Astron Research 37
HRA Pharma Enters Into Co-Marketing Agreement With Gedeon Richter 38
Gedeon Richter Enters Into A Distribution Agreement With Orexo 39
ProStrakan Enters Into Distribution Agreement With Gedeon Richter 40
Gedeon Richter Enters Into An Agreement With Repros Therapeutics 41
KV Pharma Acquires Rights From Gedeon Richter 42
DSM Biologics And Crucell Enter Into Licensing Agreement With Gedeon Richter 43
Gedeon Richter Enters Into Licensing Agreement With Mitsubishi Pharma 44
Gedeon Richter Expands Licensing Agreement With HRA Pharma 45
Phosphagenics Enters Into Licensing Agreement With Themis Medicare 46
Watson Labs Enters Into Licensing Agreement With PregLem For Esmya 47
Gedeon Richter Enters Into Licensing Agreement With Mochida Pharma 49
PregLem Enters Into Licensing Agreement With Merck Serono 50
PregLem Enters Into Licensing Agreement With HRA Pharma 52
KV Pharma Enters Into Licensing Agreement With Gedeon Richter 53
HRA Pharma Enters Into Licensing Agreement With PregLem 54
Ipsen Signs An Agreement With Preglem 55
Gedeon Richter Acquires PregLem From Ipsen And Sofinnova 56
Gedeon Richter Acquires 50% Stake In Medimpex UK From EGIS Pharma 59
Gedeon Richter Acquires 29.6% Stake In Grodziskie Zaklady Farmaceutyczne 60
Hungaropharma Acquires Medimpex Pharma From Gedeon And EGIS 62
Gedeon Richter Acquires 80.62% Stake Of Akrihin 64
Gedeon Richter Acquires 95.78% Stake In Pharmafarm 66
Gedeon Richter And Helm Acquire Strathmann Biotec 67
Armedica Trading Acquires Dita Group 69

List of Figures
List of Figures
Gedeon Richter Plc - Pipeline by Indication, 2012 8
Gedeon Richter Plc - Pipeline by Stage of Development, 2012 9
Gedeon Richter Plc - Monotherapy Products in Pipeline, 2012 10
Gedeon Richter Plc - Pipeline Products By Mechanism of Action, 2012 16

Title Date Price
2013 Deep Research Report on China Human Use Rabies Vaccine Industry
By QYResearch
2013 Deep Research Report on China Human Use Rabie Vaccine Industry is a professional and depth research report on China Human Use Rabies Vaccine industry. This report has firstly introduced Human Use ...Read More
Jan 2013 $2000.00
By Netscribes (India) Pvt. Ltd.
May 2012 $0.00
Abortion- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
By Delveinsight
DelveInsight’s, “ Abortion- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014”, report provides comprehensive insights about phase III pipeline drugs and marketed ...Read More
$2000.00
Abscess- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
By Delveinsight
DelveInsight’s, “ Abscess- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014”, report provides comprehensive insights about phase III pipeline drugs and marketed ...Read More
$2000.00
Absence Seizure- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
By Delveinsight
DelveInsight’s, “ Absence Seizure- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014”, report provides comprehensive insights about phase III pipeline drugs and m ...Read More
$2000.00
Acid Indigestion / Heartburn/ Pyrosis- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
By Delveinsight
DelveInsight’s, “ Acid Indigestion / Heartburn/ Pyrosis- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014”, report provides comprehensive insights about phase II ...Read More
$2000.00
Acne Vulgaris- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
By Delveinsight
DelveInsight’s, “ Acne Vulgaris- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014”, report provides comprehensive insights about phase III pipeline drugs and mar ...Read More
$2000.00
Acquired (Autoimmune) Hemolytic Anemia- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
By Delveinsight
DelveInsight’s, “ Acquired (Autoimmune) Hemolytic Anemia- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014”, report provides comprehensive insights about phase I ...Read More
$2000.00
Actinic (Solar) Keratosis- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
By Delveinsight
DelveInsight’s, “ Actinic (Solar) Keratosis- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014”, report provides comprehensive insights about phase III pipeline d ...Read More
$2000.00
Actinomycosis Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
By Delveinsight
DelveInsight’s, “ Actinomycosis- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014”, report provides comprehensive insights about phase III pipeline drugs and mar ...Read More
$2000.00

  * Required field
Name *
E-mail *
Telephone 
Company *
Country *
Query 
 
   

   
For support please
contact:
US Toll Free
+1 888-789-6604
Asia Pacific
+91-9893555190
 
 
To receive alerts about
an update, future offers and discounts on this report, signup here.
Email ID
 

Companies


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Countries


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z